scholarly journals Autologous Blood Products: When, Where, and How?

2021 ◽  
Vol 8 (1) ◽  
pp. 1-9
Author(s):  
Alfonso L Sabater ◽  
Keyword(s):  
Ocular Surface ◽  
Keratoconjunctivitis Sicca ◽  
Therapeutic Option ◽  
Autologous Blood ◽  
Stevens Johnson Syndrome ◽  
Eye Drops ◽  
Corneal Epithelial ◽  
Johnson Syndrome ◽  
Ocular Surface Diseases ◽  
Persistent Epithelial Defects

Autologous blood eye drops have become an interesting, well-known, and widely used therapeutic option for many ocular surface diseases since their introduction into the ophthalmologic field forty-six years ago. The foundation for their use in the treatment of pathologies such as severe keratoconjunctivitis sicca, persistent epithelial defects, ocular chemical burns, recurrent epithelial erosions, Stevens-Johnson syndrome, ocular graft versus host disease, and, lately, in many other ocular surface conditions, relies on the fact that they contain proteins, vitamins, cytokines, and growth factors that participate in the signaling pathways of corneal epithelial healing in similar amounts to those found in normal, healthy tear films

Indications of Scleral Contact Lenses in Ocular Surface Diseases

2021 ◽  
Author(s):  
Sudhanshu Dhanotia
Keyword(s):  
Ocular Surface ◽  
Contact Lenses ◽  
Patient Comfort ◽  
Stevens Johnson Syndrome ◽  
Visual Rehabilitation ◽  
Johnson Syndrome ◽  
Ocular Surface Diseases ◽  
Neurotrophic Keratitis ◽  
Traditional Therapies ◽  
Improve Patient

The use of scleral lenses is increased over the last decade. Not only it helps in the patient’s visual rehabilitation but also provides wearing comfort to the patient. Previously scleral lenses were mostly prescribed in cases where traditional therapies don’t work well. But nowadays due to advanced designing and customized fitting this lens are widely prescribed in various ocular surface diseases where these lenses not only improve patient comfort but act as an important tool in promoting healing of the corneal epithelium. Therapeutic Scleral lens indications include DED syndrome, exposure keratitis, graft-versus-host disease, Stevens-Johnson syndrome, ocular cicatri¬cial pemphigoid, persistent epithelial defects, neurotrophic keratitis, chemical burns, limbal stem cell deficiency etc.

scholarly journals Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jayoon Moon ◽  
Sang-Mok Lee ◽  
Joon Young Hyon ◽  
Mee Kum Kim ◽  
Joo Youn Oh ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Ocular Surface ◽  
Large Diameter ◽  
Signs And Symptoms ◽  
Stevens Johnson Syndrome ◽  
Ocular Surface Disease Index ◽  
Fluorescein Staining ◽  
Counting Finger ◽  
Johnson Syndrome ◽  
Ocular Surface Diseases

AbstractTo report the efficacy and safety of large diameter scleral lenses and determine their suitability in Asian subjects with intractable ocular surface diseases. This prospective study enrolled intractable ocular surface diseases subjects with uncorrected visual acuity > counting finger but ≥ 0.3 logMAR and best-corrected visual acuity (BCVA) ≥ 0.3 logMAR, to fit large diameter scleral lenses for 12 weeks. 21 eyes (13 subjects) consisting ten eyes (47.6%) with persistent epithelial defects, 6 (28.6%) with graft-versus-host disease, 4 (19.0%) with Stevens–Johnson syndrome and one (4.8%) with severe dry eye were ultimately enrolled. Primary outcome measures were the visual acuity, corneal and conjunctival fluorescein staining, Ocular Surface Disease Index (OSDI), and National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25). At week 12 with large diameter scleral lenses, BCVA improved from 0.77 logMAR to 0.27 logMAR (P < 0.001). High-grade corneal and conjunctival fluorescein staining proportion decreased from 61.90 to 14.29% and 52.38 to 9.52%, respectively (P = 0.0036 and 0.0063, respectively). OSDI and NEI-VFQ-25 improved from 67.89 to 34.69 and 51.40 to 64.48, respectively (P < 0.001). No adverse effects were observed. In Asians with intractable ocular surface diseases, large diameter scleral lens improves visual acuity and alleviates signs and symptoms of ocular surface diseases without any significant complications.Trial registration Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Project No. HI12C0015 (A120018)). Clinical Trials.gov, NCT04535388. Registered 18 August 2020—Retrospectively registered, http://clinicaltrials.gov/ct2/show/NCT04535388.

Long-term Progression of Ocular Surface Disease in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis

Cornea ◽  
2020 ◽  
Vol 39 (6) ◽  
pp. 745-753
Author(s):  
Yamato Yoshikawa ◽  
Mayumi Ueta ◽  
Hideki Fukuoka ◽  
Tsutomu Inatomi ◽  
Isao Yokota ◽  
...  
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Ocular Surface ◽  
Ocular Surface Disease ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice

2021 ◽  
Author(s):  
Noelia Sabater-Cruz ◽  
◽  
Marc Figueras-Roca ◽  
Miriam Ferrán-Fuertes ◽  
Elba Agustí ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Amniotic Membrane ◽  
Real World ◽  
Ocular Surface ◽  
Eye Drops ◽  
Ocular Surface Diseases ◽  
Membrane Extract

scholarly journals Keratoconjunctivitis associated with nevirapine toxicity in HIV pregnant woman

2012 ◽  
Vol 2 (1) ◽  
pp. 6
Author(s):  
Bety Yañez
Keyword(s):  
Highly Active Antiretroviral Therapy ◽  
Stevens Johnson Syndrome ◽  
Amniotic Membrane Transplantation ◽  
Eye Drops ◽  
Highly Active ◽  
Johnson Syndrome ◽  
Immunodeficiency Virus ◽  
Acquired Immunodeficiency ◽  
The Right ◽  
Immunodeficiency Syndrome

Highly active antiretroviral therapy (HAART) is the treatment of choice for human immunodeficiency virus-acquired immunodeficiency syndrome (HIV-AIDS) patients. Severe side effects of these drugs have been described that produce generalized autoimmune blistering diseases, such as Stevens-Johnson syndrome and toxic epidermal necrosis (TEN). These complications may seriously compromise the patient&rsquo;s life or cause disabling consequences such as blindness. We describe a case of 21-year old female HIV patient with a CD4 count of 126 cells/microliter. Ten days post elective caesarean delivery she restarted HAART with nevirapine and developed TEN after approximately two weeks. Nevirapine was discontinued, but despite this, ocular surface disorder persisted. She presented severe bilateral keratoconjunctivitis that was treated with free tear substitutes, moxifloxacyn, and prednisolone acethate eye drops. At 2-month follow up her visual acuity without correction was 20/160 in the right eye and 20/40 in the left. She had bilateral moderate cicatricial keratoconjunctivitis and a central corneal leukoma in the right eye. Early treatment is important and should consist of preservative-free lubricants, and amniotic membrane transplantation to decrease the frequency of severe sequelae such as keratitis and corneal leukomas that will reduce the quality of life for these patients.

scholarly journals Utilization of metabolic energy in treatment of ocular surface disorders: polyphosphate as an energy source for corneal epithelial cell proliferation

RSC Advances ◽  
2019 ◽  
Vol 9 (39) ◽  
pp. 22531-22539 ◽  
Author(s):  
Adrian Gericke ◽  
Xiaohong Wang ◽  
Maximilian Ackermann ◽  
Meik Neufurth ◽  
Matthias Wiens ◽  
...  
Keyword(s):  
Energy Source ◽  
Cell Proliferation ◽  
Ocular Surface ◽  
Clinical Problem ◽  
Metabolic Energy ◽  
Corneal Epithelial Cell ◽  
Epithelial Cell Proliferation ◽  
Corneal Epithelial ◽  
Ocular Surface Diseases ◽  
Major Clinical Problem

Impaired regeneration of the corneal epithelium, as found in many ocular surface diseases, is a major clinical problem in ophthalmology.

scholarly journals Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Francesco Semeraro ◽  
Eliana Forbice ◽  
Osvaldo Braga ◽  
Alessandro Bova ◽  
Attilio Di Salvatore ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Conventional Therapy ◽  
Keratoconjunctivitis Sicca ◽  
Signs And Symptoms ◽  
Autologous Serum ◽  
Eye Drops ◽  
Blurred Vision ◽  
Group 2 ◽  
Serum Eye Drops ◽  
Group 1

Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.Methods. We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.

Sign in / Sign up

Export Citation Format

Share Document